Abstract
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of addi...
Cite
CITATION STYLE
APA
Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., … Monk, B. J. (2021). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. New England Journal of Medicine, 385(20), 1856–1867. https://doi.org/10.1056/nejmoa2112435
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free